Observational studyActa diabetologica2023
Diabetic patients with and without sodium-glucose cotransporter-2 inhibitors use and cataract risk: real-world observational investigation.
Observational study in Acta diabetologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glutaredoxin 2 Protects Lens Epithelial Cells From Ferroptosis by Preventing HNRNPA2B1 S-Glutathionylation in Diabetes-Mediated Cataractogenesis.Investigative ophthalmology & visual science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe tried to define the association of type 2 diabetes mellitus (T2DM) patients with and without sodium-glucose cotransporter-2 inhibitors (SGLT2I) use and incident cataract using nationwide data in Taiwan.
methodsIn a Cox proportional hazards regression model, we estimated the hazard ratios (HR) and 95% confidence intervals (95% CI). We considered risk factors for variables of sex, age, comorbidities and medications that we adjusted in multivariable Cox model.
resultsWe identified 20,768 T2DM patients in this study; 10,384 patients in the SGLT2I cohort, and 10,384 controls in the non-SGLT2I cohort. Compared with the T2DM patients without SGLT2I, T2DM patients using SGLT2I had a 2.04-fold increased risk of cataract, after adjustment by sex, age, comorbidities and medications.
conclusionIncreased risk of cataract among diabetic patients who took SGLT2I was found in this study.
Indexed as
Identifiers
37083962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.